Helix Biopharm (HBP.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 07/31
| 01-2022 | 10-2021 | 07-2021 | 04-2021 | 01-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 471 | 1,873 | 3,565 | 2,266 | 4,098 |
| Receivables | 319 | 309 | 353 | 392 | 390 |
| TOTAL | $902 | $2,269 | $4,018 | $2,936 | $4,874 |
| Non-Current Assets | |||||
| PPE Net | 41 | 44 | 47 | 87 | 127 |
| TOTAL | $41 | $44 | $47 | $87 | $127 |
| Total Assets | $944 | $2,313 | $4,065 | $3,023 | $5,001 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,940 | 2,037 | 2,028 | N/A | N/A |
| Accounts payable and accrued liabilities | 1,579 | 1,416 | 1,466 | 1,265 | 841 |
| Accrued Expenses | 493 | 309 | 380 | 414 | 327 |
| TOTAL | $4,012 | $3,762 | $3,874 | $1,713 | $1,235 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,024 | 1,281 | 1,584 | N/A | N/A |
| TOTAL | $1,024 | $1,281 | $1,584 | $0 | $0 |
| Total Liabilities | $5,036 | $5,043 | $5,458 | $1,713 | $1,235 |
| Shareholders' Equity | |||||
| Common Shares | 140,483 | 140,071 | 139,660 | 139,660 | 139,660 |
| Retained earnings | -192,386 | -190,367 | -188,554 | -185,784 | -183,230 |
| Other shareholders' equity | 19,944 | 19,699 | 19,634 | 20,103 | 20,135 |
| TOTAL | $-4,092 | $-2,730 | $-1,393 | $1,310 | $3,766 |
| Total Liabilities And Equity | $944 | $2,313 | $4,065 | $3,023 | $5,001 |